Rhythm Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RYTM and other ETFs, options, and stocks.

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. 

CEO
David P. Meeker
CEODavid P. Meeker
Employees
414
Employees414
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2008
Founded2008
Employees
414
Employees414

RYTM Key Statistics

Market cap
5.93B
Market cap5.93B
Price-Earnings ratio
-27.63
Price-Earnings ratio-27.63
Dividend yield
—
Dividend yield—
Average volume
814.39K
Average volume814.39K
High today
$88.62
High today$88.62
Low today
$85.91
Low today$85.91
Open price
$88.20
Open price$88.20
Volume
351.77K
Volume351.77K
52 Week high
$122.20
52 Week high$122.20
52 Week low
$74.50
52 Week low$74.50

Stock Snapshot

With a market cap of 5.93B, Rhythm Pharmaceuticals(RYTM) trades at $86.17. The stock has a price-to-earnings ratio of -27.63.

As of 2026-10-17, Rhythm Pharmaceuticals(RYTM) stock has fluctuated between $85.91 and $88.62. The current price stands at $86.17, placing the stock +0.3% above today's low and -2.8% off the high.

The Rhythm Pharmaceuticals(RYTM)'s current trading volume is 351.77K, compared to an average daily volume of 814.39K.

During the past year, Rhythm Pharmaceuticals(RYTM) stock moved between $74.50 at its lowest and $122.20 at its peak.

During the past year, Rhythm Pharmaceuticals(RYTM) stock moved between $74.50 at its lowest and $122.20 at its peak.

RYTM News

Investing.com 3d
Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity - Investing.com

...

Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity - Investing.com
Simply Wall St 4d
Did Prader Willi Therapy Progress Just Shift Rhythm Pharmaceuticals' Investment Narrative?

Rhythm Pharmaceuticals has seen sentiment improve after recent developments in Prader-Willi syndrome care, including clinical and regulatory progress around its...

Did Prader Willi Therapy Progress Just Shift Rhythm Pharmaceuticals' Investment Narrative?

Analyst ratings

90%

of 20 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own RYTM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.